Ipsen set to buy Merrimak’s cancer drugs in $1billion deal
French drugmaker Ipsen SA said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc., including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial. The deal would give Merrimack the resources to fund the development of three new compounds targeting… Read More Ipsen set to buy Merrimak’s cancer drugs in $1billion deal